Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Structure-guided drug discovery: back to the future

Over the past 30 years, the field of structural biology and its associated biological insights have seen amazing progress. In this Comment, I recount several milestones in the field and how we can apply lessons from the past toward an exciting future, especially as it relates to drug discovery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Frye, S. Nat. Chem. Biol. 6, 159–161 (2010).

    Article  CAS  PubMed  Google Scholar 

  2. Arrowsmith, C. et al. Nat. Chem. Biol. 11, 536–541 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Edwards, A. et al. Nature 470, 163–165 (2011).

    Article  ADS  CAS  PubMed  Google Scholar 

  4. Carter, A. J. et al. Drug Discov. Today 26, 607–612 (2019).

    Google Scholar 

  5. Jumper, J. et al. Nature 596, 583–589 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Baek, M. et al. Science 373, 871–876 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kryshtafovych, A., Schwede, T., Topf, M., Fidelis, K. & Moult, J. Proteins 91, 1539–1549 (2020).

    Article  Google Scholar 

  8. Nature 617, 438 (2023).

  9. Ackloo, S. et al. Nat. Rev. Chem. 6, 287–295 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references


C.H.A. is funded by the Canadian Institutes for Health Research (FDN154328 and OGB190363), Canada foundation for Innovation, National Institutes of Health (U19 AI171292), Huntington Society of Canada, Princess Margaret Cancer Centre, The Princess Margaret Cancer Foundation, and Ontario Ministry of Health. The Structural Genomics Consortium is a registered charity (no. 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute (OGI-196), EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant 875510), Janssen, Merck (known as EMD in Canada and the United States), Pfizer and Takeda.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Cheryl H. Arrowsmith.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arrowsmith, C.H. Structure-guided drug discovery: back to the future. Nat Struct Mol Biol 31, 395–396 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research